- 1 What is the potential benefit?
- 2 Who is a suitable candidates?
- 3 Who is NOT a suitable candidate for an autologous biocellular treatment?
- 4 What skin, soft tissue, and musculoskeletal tissues can be treated?
- 5 What are the risks?
- 6 What is the price range for an autologous biocellular treatment at MRM?
- 7 At which locations is the treatment performed?
- 8 What if I am a suitable candidate for treatment?
- 9 Where do the regenerative cell populations come from?
- 10 What is the success rate?
- 11 Does treatment consist of one or multiple injections?
- 12 Free Consultation
What is the potential benefit?
Autologous (patient-derived) biocelluar treatments containing bone marrow aspirate concentrate (BMAC) or fat aspirate concentrate (FAC) with cell populations of regenerative cells, including mesenchymal stem cells, stromal cells, progenitor cells, endothelial cells, lymphocytes, macrophages, and pericytes, provide a non-surgical treatment option to reduce pain and to promote natural healing and tissue regeneration, while still providing long-lasting relief, or potentially a cure, from a degenerative skin or soft tissue or musculoskeletal condition.
Who is a suitable candidates?
In general, autologous (patient-derived) biocellular treatments can be appropriate for patients suffering from a degenerative skin, soft tissue, or musculoskeletal condition. This includes mild to moderate osteoarthritis affecting body areas such as the knee, shoulder, hip, ankle, foot, hand, or digits. Biocellular treatments can also be appropriate for patients with skin and soft tissue conditions such as aging skin, wounds, scars, scalp hair loss or miniaturization or balding, men’s sexual health issues, chronic tendinitis, partially torn tendons, and damaged musculoskeletal tissues, including damage or degeneration of the rotator cuff, labrum, meniscus, or avascular necrosis of bone.
Who is NOT a suitable candidate for an autologous biocellular treatment?
Conditions excluding a patient from being a suitable candidate for an autologous biocellular treatment at MRM include:
- a patient with active cancer not in remission for at least 5 years; or prior lymphoma, leukemia
- a patient with a current or active infection
- a patient needing to take blood thinners (such as Coumadin or Warfarin)
- a patient needing to take anti-platelet medications (such as to prevent stroke or stenosis of coronary stent)
- a patient with a contraindication to having bone marrow harvested, or fat harvested by liposuction, or whole blood collected by venipuncture
- a patient with complex or severe medical issues
- an elderly patient, perhaps beyond age 80 (since the number and capability of regenerative cell populations decrease with advancing age)
What skin, soft tissue, and musculoskeletal tissues can be treated?
The most common degenerative conditions treated with BMAC, FAC, and HD-PRP include the scalp for biocellular hair restoration, the face for skin regeneration and fat volume replacement, the hands for skin rejuvenation, scars and wounds for skin and soft tissue regeneration, the penis for tissue regeneration, and the knee, shoulder, hip, ankle, hand, digits, and tendons for musculoskeletal tissue regeneration.
What are the risks?
An autologous biocellular treatment is a safe surgical treatment with minimal risks. Since the regenerative cells come from your own body, there is no chance of rejection or allergic reaction to these biocellular agents. There is a small risk of infection following a biocellular treatment, ust like with any surgical procedure. However, prophylactic antibiotics and sterilizing skin preparations are used at MRM for all BMAC, FAC, and HD-PRP treatments. You can expect some soreness for a few days at the harvest site and recipient injection site following the procedure.
What is the price range for an autologous biocellular treatment at MRM?
The price for a biocellular treatment at MRM that involves injection of BMA, FA, HD-PRP, or a combination of the three, inclusive of precision image guidance with fluoroscopy and/or ultrasonagraphy, ranges from $950 to $10,000. The selection of biocellular agents and the number of degenerative areas that can be treated during a single stem cell (SVF) treatment session will vary, depending on patient choice, physician recommendation, and the amount of isolated biocellular agents.
Treatments with bone marrow aspirate concentrate (BMAC), fat aspirate concentrate (FAC), and HD-PRP are not a covered benefit of Medicare or private insurance. Payment is due and payable to Minnesota Regenerative Medicine prior to treatment.
At which locations is the treatment performed?
Our regenerative medicine specialists at Minnesota Regenerative Medicine currently provide BMAC, FAC, and HD-PRP treatments only at our Maple Grove facility. A complete biocellular treatment session usually takes up to several hours to perform.
What if I am a suitable candidate for treatment?
If you can make the trip, we recommend that you schedule an appointment for a regenerative medicine consultation to determine if you are a suitable candidate for an autologous biocellular treatment. To expedite this process, we ask that you bring with you a copy of any MRI, X-ray, imaging, or radiology typed reports for our specialists to read, as well as any other pertinent medical records.
Where do the regenerative cell populations come from?
The regenerative cell populations originate from the patient’s own bone marrow or fat tissue or whole blood.
What is the success rate?
Since we began performing autologous biocellular treatments in 2011, our experience is that most patients experience pain relief and functional improvement of their treated degenerative conditions. It is rare for a patient not to experience some degree of pain relief or functional improvement at MRM following a BMAC, FAC, or HD-PRP treatment.
Sometimes, for large joints such as shoulders and knees, we recommend high-density platelet-rich plasma (HD-PRP) injections be performed monthly for 2 consecutive months after the initial BMAC and/or FAC, HD-PRP treatment in order to maximize treatment results. This recommendation is based on the understanding that since growth factors and bioactive agents in HD-PRP stimulate neighboring regenerative cell populations to continue to divide and differentiate. Each HD-PRP treatment beyond the initial BMAC, FAC, HD-PRP treatment session will incur an additional charge. Ongoing clinical improvement following a BMAC, FAC, HD-PRP treatment can continue for a year or two. Of the many patients treated so far at MRM, the majority of patients asked during their follow-up visits have self-reported ongoing significant pain relief, functional improvement, and signs of tissue healing following BMAC, FAC, and HD-PRP treatment.
Does treatment consist of one or multiple injections?
The number of injections per treatment session varies, depending on the size, severity and complexity of the degenerative condition being treated. The needles used at MRM are small in diameter, since the solution containing either the BMAC, FAC, or HD-PRP is often close to the consistency of water. This is in contrast to the large needles required to inject thick viscous solutions such as corticosteroids or visco-supplements (hyaluronic acid).
Our regenerative medicine specialist consults with each patient to customize a regenerative medicine treatment plan specific to their degenerative condition.